These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23745743)

  • 1. Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection.
    Yamamoto T; Ihashi M; Mizoguchi Y; Kaneno H; Yamamoto K; Inoue Y; Kase T; Okabe N; Shimotsuji T
    Pediatr Int; 2013 Dec; 55(6):714-21. PubMed ID: 23745743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza.
    Nabeshima S; Kashiwagi K; Ajisaka K; Masui S; Takeoka H; Ikematsu H; Kashiwagi S
    J Infect Chemother; 2012 Aug; 18(4):534-43. PubMed ID: 22350323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
    Kawai N; Ikematsu H; Kawashima T; Maeda T; Ukai H; Hirotsu N; Iwaki N; Kashiwagi S
    Influenza Other Respir Viruses; 2013 May; 7(3):448-55. PubMed ID: 22897904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study.
    Miller PE; Rambachan A; Hubbard RJ; Li J; Meyer AE; Stephens P; Mounts AW; Rolfes MA; Penn CR
    PLoS One; 2012; 7(9):e43491. PubMed ID: 22984431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
    Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
    J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
    Muthuri SG; Venkatesan S; Myles PR; Leonardi-Bee J; Al Khuwaitir TS; Al Mamun A; Anovadiya AP; Azziz-Baumgartner E; Báez C; Bassetti M; Beovic B; Bertisch B; Bonmarin I; Booy R; Borja-Aburto VH; Burgmann H; Cao B; Carratala J; Denholm JT; Dominguez SR; Duarte PA; Dubnov-Raz G; Echavarria M; Fanella S; Gao Z; Gérardin P; Giannella M; Gubbels S; Herberg J; Iglesias AL; Hoger PH; Hu X; Islam QT; Jiménez MF; Kandeel A; Keijzers G; Khalili H; Knight M; Kudo K; Kusznierz G; Kuzman I; Kwan AM; Amine IL; Langenegger E; Lankarani KB; Leo YS; Linko R; Liu P; Madanat F; Mayo-Montero E; McGeer A; Memish Z; Metan G; Mickiene A; Mikić D; Mohn KG; Moradi A; Nymadawa P; Oliva ME; Ozkan M; Parekh D; Paul M; Polack FP; Rath BA; Rodríguez AH; Sarrouf EB; Seale AC; Sertogullarindan B; Siqueira MM; Skręt-Magierło J; Stephan F; Talarek E; Tang JW; To KK; Torres A; Törün SH; Tran D; Uyeki TM; Van Zwol A; Vaudry W; Vidmar T; Yokota RT; Zarogoulidis P; ; Nguyen-Van-Tam JS
    Lancet Respir Med; 2014 May; 2(5):395-404. PubMed ID: 24815805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza.
    Mawatari M; Saito R; Hibino A; Kondo H; Yagami R; Odagiri T; Tanabe I; Shobugawa Y;
    PLoS One; 2019; 14(11):e0224683. PubMed ID: 31697721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of neuraminidase inhibitors for the treatment of Japanese patients infected with the novel influenza A (H1N1).
    Ohnishi K; Nakamura-Uchiyama F
    J Infect Chemother; 2010 Feb; 16(1):62-3. PubMed ID: 20072797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
    Hishiki H; Ishiwada N; Naito S; Nagasawa K; Someya T; Inoue N; Haraki M; Kurosaki T; Kameoka Y; Suzuki K
    Jpn J Antibiot; 2015 Dec; 68(6):337-43. PubMed ID: 27004397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of neuraminidase inhibitors for severe influenza.
    Fry AM
    Lancet Respir Med; 2014 May; 2(5):346-8. PubMed ID: 24815800
    [No Abstract]   [Full Text] [Related]  

  • 15. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
    Liu H; Yao X; Wang C; Han J
    Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Wolkewitz M; Schumacher M
    Lancet Respir Med; 2014 Jul; 2(7):e8-9. PubMed ID: 24948434
    [No Abstract]   [Full Text] [Related]  

  • 17. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Leonardi-Bee J; Venkatesan S; Muthuri SG; Nguyen-Van-Tam JS; Myles PR;
    Lancet Respir Med; 2014 Jul; 2(7):e10-2. PubMed ID: 24948433
    [No Abstract]   [Full Text] [Related]  

  • 18. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Jones M; Del Mar C; Hama R
    Lancet Respir Med; 2014 Jul; 2(7):e9-e10. PubMed ID: 24948431
    [No Abstract]   [Full Text] [Related]  

  • 19. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Antes G; Meerpohl JJ
    Lancet Respir Med; 2014 Jul; 2(7):e10. PubMed ID: 24948429
    [No Abstract]   [Full Text] [Related]  

  • 20. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.